Defence Therapeutics Stock Quote DTC - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

0.99

Bid

0.99

Ask

1.20

Volume

114,536

0.96 Day's Range 1.17

0.48 52 Week Range 2.05

Previous Close

1.15

Open

1.17

Last Trade

1500

0.99

Last Trade Time

Average Volume (3m)

80,086

Financial Volume

VWAP

FeaturedImagineAR's FameDays Secures $10 Million Contract to Develop 25,000 Sq. Ft. Immersive Entertainment Center at a Niagara Falls Hotel in Canada

DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER

DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER Vancouver, BC, Canada, February 16th, 2022...

Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9

Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to...

DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT

Vancouver, BC, Canada -- November 30th 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. (CSE: DTC; FSE: DTC; USOTC:...

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER Vancouver, BC, Canada...

DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS

DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS Vancouver, BC, Canada, November 9th, 2021 -- InvestorsHub NewsWire...

VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS

VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN...

DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER

DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST...

DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA

DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA Vancouver, BC, Canada, October...

DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER

DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER Vancouver, BC, Canada, September 29th, 2021...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.31	-23.8461538462	1.3	1.66	0.96	267788	1.474839	CS
4	-0.01	-1	1	1.66	0.94	146297	1.30150584	CS
12	0.46	86.7924528302	0.53	1.66	0.49	80086	1.08613692	CS
26	0.35	54.6875	0.64	1.66	0.48	49343	0.94757475	CS
52	-0.96	-49.2307692308	1.95	2.05	0.48	42171	1.01994469	CS
156	-3.03	-75.3731343284	4.02	4.85	0.48	24478	1.84244605	CS
260	-0.76	-43.4285714286	1.75	8.15	0.48	22051	2.27058615	CS

DTC - Frequently Asked Questions (FAQ)

What is the current Defence Therapeutics share price?

The current share price of Defence Therapeutics is $ 0.99

What is the 1 year trading range for Defence Therapeutics share price?

Defence Therapeutics has traded in the range of $ 0.48 to $ 2.05 during the past year

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CDVACordovaCann Corp	$ 0.07 (133.33%)	59k
IANiAnthus Capital Holdings Inc	$ 0.01 (100.00%)	65.53k
CVGRCity View Green Holdings Inc	$ 0.01 (100.00%)	414.53k
NINENine Mile Metals Ltd	$ 0.015 (50.00%)	1.82M
QREEQuebec Rare Earth Elements Corp	$ 0.075 (50.00%)	74k
TUGATuga Innovations Inc	$ 0.005 (-50.00%)	1,000
AUEXAdvanced Gold Exploration Inc	$ 0.005 (-50.00%)	25k
CLICape Lithium Corp	$ 0.01 (-50.00%)	888k
NWAINew Wave Holdings Corp	$ 0.015 (-50.00%)	580.17k
FUTRGold n Futures Mineral Corp	$ 0.005 (-50.00%)	100k
CSSCascada Silver Corp	$ 0.035 (-30.00%)	3.88M
IPImagineAR Inc	$ 0.08 (-27.27%)	2.4M
QIMCQuebec Innovative Materials Corp	$ 0.235 (27.03%)	2.35M
NINENine Mile Metals Ltd	$ 0.015 (50.00%)	1.82M
WHIPCredissential Inc	$ 0.055 (-15.38%)	1.69M

Man6677 3 years ago

Why are there no trades here ?

Thank you !

Great news today !

👍️0

newspopper 3 years ago

Get in KITL .08-.10 news will be poppin

👍️0

newspopper 3 years ago

Need more volume for Poppin action

👍️0

newspopper 3 years ago

Looking for FDA Poppin news

👍️0

newspopper 3 years ago

KITL news going to be poppin

👍️0

GOLDBUFFALO 3 years ago

Seems to be a very interesting stock.

👍️0

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Defence Therapeutics Inc (DTC)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Ask ADVFN Intelligence (AI)

DTC Latest News

FeaturedImagineAR's FameDays Secures $10 Million Contract to Develop 25,000 Sq. Ft. Immersive Entertainment Center at a Niagara Falls Hotel in Canada

DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER

Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9

DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER

DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS

VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS

DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER

DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA

DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER

FeaturedImagineAR's FameDays Secures $10 Million Contract to Develop 25,000 Sq. Ft. Immersive Entertainment Center at a Niagara Falls Hotel in Canada

DTC - Frequently Asked Questions (FAQ)

Movers

DTC Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Defence Therapeutics Inc (DTC) Quote

Defence Therapeutics Inc (DTC)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Ask ADVFN Intelligence (AI)

DTC Latest News

FeaturedImagineAR's FameDays Secures $10 Million Contract to Develop 25,000 Sq. Ft. Immersive Entertainment Center at a Niagara Falls Hotel in Canada

DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER

Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9

DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT

DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER

DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS

VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS

DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER

DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA

DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER

FeaturedImagineAR's FameDays Secures $10 Million Contract to Develop 25,000 Sq. Ft. Immersive Entertainment Center at a Niagara Falls Hotel in Canada

DTC - Frequently Asked Questions (FAQ)

Movers

DTC Discussion

Your Recent History

Go Ad-Free